Finding What Works in Health Care: Standards for Systematic Reviews (2011)
Chapter: Appendix C: Workshop Agenda and Questions to Panelists
C
Workshop Agenda and Questions to Panelists
January 14, 2010
Keck Center of The National Academies
500 Fifth Street, N.W., Room 100
Washington, DC
Workshop Objective: To learn how various stakeholders use and develop systematic reviews (SRs), including expert developers of SRs, professional specialty societies, payers, and consumer advocates.
|
8:00 |
Breakfast served |
|
8:30 |
Welcome and Introductory Remarks Alfred O. Berg, Chair, Institute of Medicine Committee |
|
8:45 |
Systematic Review Experts Panel |
|
Kalipso Chalkidou, Director, NICE International, National Institute for Health and Clinical Excellence Naomi Aronson, Executive Director, Technology Evaluation Center, Blue Cross and Blue Shield Association David B. Wilson, Crime and Justice Group Cochair, Steering Committee, The Campbell Collaboration Moderator: Kay Dickersin, Professor of Epidemiology, Johns Hopkins Bloomberg School of Public Health |
|
9:45 |
Professional Specialty Societies Panel |
|
Virginia Moyer, Section Head, Academic General Pediatrics, Baylor College of Medicine Sandra Zelman Lewis, Assistant Vice President, Health & Science Policy, American College of Chest Physicians Rebekah Gee, Assistant Professor of Clinical Medicine, Department of Obstetrics and Gynecology, Tulane University Moderator: Harold C. Sox, Editor Emeritus, Annals of Internal Medicine |
|
|
10:45 |
Break |
|
11:00 |
The Payer Perspective Panel |
|
Louis B. Jacques, Director, Coverage & Analysis Group, Office of Clinical Standards & Quality, Centers for Medicare & Medicaid Services Alan Rosenberg, Vice President of Technology Assessment, WellPoint Health Networks Edmund Pezalla, National Medical Director and Chief Clinical Officer, Aetna Pharmacy Management Moderator: Paul Wallace, Medical Director, The Permanente Federation, Kaiser Permanente |
|
|
12:00 |
Lunch |
|
12:30 |
Consumer Panel |
|
Gail Shearer, Former Director, Consumer Reports Best Buy Drugs, and Former Director, Health Policy Analysis, Consumers Union David Shern, President and Chief Executive Officer, Mental Health America Carol Sakala, Director of Programs, Childbirth Connection Moderator: Katie Maslow, Director, Policy Development, Alzheimer’s Association |
|
|
1:30 |
Adjourn |
Questions for the Panelists
Systematic Review Experts Panel
-
How do you develop your review questions?
-
To what extent is the user involved in developing the research question?
-
-
How do you determine the inclusion criteria for studies in your evidence synthesis?
-
Do you incorporate observational and other nonrandomized data? If yes, what are the parameters for their use?
-
Do you incorporate unpublished and grey literature? Please explain.
-
How do you protect against publication and reporting (outcome) bias? What have been the challenges (if any)?
-
-
Do you use any specific instruments or methods to ensure the quality of your SRs?
-
What are the greatest challenges in producing SRs that meaningfully support users’ decisions?
-
How do your “customers” use your reviews?
-
How are your reviews funded? Do you accept industry funding? How do you identify and address potential conflicts of interest (COIs)?
-
This Institute of Medicine (IOM) committee is charged with recommending standards for SRs of comparative effectiveness research (CER). Are there steps in your SR process that could be standardized?
-
What would be the implications if the IOM were to recommend a standard grading scheme for characterizing the strength of evidence?
Professional Specialty Societies Panel
-
Does your organization produce its own SRs?
-
If yes, have you developed or adopted standards or guidance for the process? Please describe.
-
If no, who produces your SRs? To what extent does your organization participate in the review?
-
-
What are the greatest challenges in using SRs to develop clinical practice guidelines (CPGs)?
-
How are your SRs funded? Do you accept industry funding? How do you identify and address potential COIs?
-
Do you use any specific instruments or methods to ensure the quality of your SRs?
-
This IOM committee is charged with recommending standards for SRs of CER. Are there steps in your SR process that could be standardized?
-
What would be the implications for your organization if the IOM were to recommend a standard grading scheme for characterizing the strength of evidence?
Payer Perspective Panel
-
Does your organization produce its own SRs?
-
If yes, have you developed or adopted standards or guidance for the process? Please explain.
-
If no, who produces your SRs? Does your organization participate in the review? Please explain.
-
-
Do you incorporate observational and other nonrandomized data in your evidence syntheses? If yes, what are the parameters for their use?
-
How do use SRs to make coverage decisions?
-
What are the greatest challenges in using SRs to inform coverage decisions?
-
This IOM committee is charged with recommending standards for SRs of CER. Are there steps in the SR process that could be standardized?
-
What would be the implications for your organization if the IOM were to recommend a standard grading scheme for characterizing the strength of evidence?
Consumer Panel
-
What should be the role of the patient/consumer in the SR process?
-
Who should be considered a consumer (e.g., members or representatives of organized groups; patients with personal experiences with a disease; any member of the public, caregivers, and parents)?
-
What lessons can be learned from existing models of consumer involvement? Based on your personal experience, where do you think that involving consumers made a real difference to the process and to the results? What aspects of consumer involvement are working well and what aspects are not working well?
-
Do consumers need training/education to participate meaningfully in the SR process?
